SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Curr Med Chem. 2023 Oct 19. doi: 10.2174/0109298673251493231011192520. Online ahead of print.ABSTRACTType 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, primarily in highly developed Western societies. T2DM causes systemic complications, such as atherosclerotic heart disease, ischemic stroke, peripheral artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. The growing number of T2DM patients and the treatment of long-term T2DM-related complications pressurize and exhaust public healthcare systems. As a result, strategies for combating T2DM and developing novel drugs a...
Source: Current Medicinal Chemistry - October 19, 2023 Category: Chemistry Authors: Nikola Lukic Mirjana T Macvanin Zoran Gluvic Manfredi Rizzo Djordje Radak Jasjit S Suri Esma R Isenovic Source Type: research
Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial
Canagliflozin is a sodium –glucose cotransporter 2 inhibitor that has been shown to reduce cardiovascular events in diabetic patients with and without heart failure (HF). Whether the clinical benefits and safety profile of canagliflozin are different in those on a beta blocker and an angiotensin-converting enzyme inhibitor /angiotensin receptor blocker (BB + RAASi) is unknown. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - October 14, 2023 Category: Cardiology Authors: Sneha S. Jain, Jie Yu, Clare Arnott, Bruce Neal, Vlado Perkovic, Brendon L. Neuen, Meg Jardine, Kenneth W. Mahaffey Tags: Short communication Source Type: research
Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
Conclusion: SGLT-2i versus oGLD was associated with a similar occurrence of LLA, UTI, and bone fracture. However, SGLT-2i was associated with a higher risk of DKA and GTI than oGLD. These findings provide valuable information on the safety profile of SGLT-2i in patients with T2DM and can help inform clinical decision-making. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - October 13, 2023 Category: Drugs & Pharmacology Source Type: research
Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
Studies reporting the effects of metabolic surgery, lifestyle intervention, and intensive insulin therapy for the remission of type 2 diabetes (T2DM) has been increasing, with fruitful results better conducted... (Source: BMC Endocrine Disorders)
Source: BMC Endocrine Disorders - October 10, 2023 Category: Endocrinology Authors: Xue Yang, Zhiwei He, Li Yuan, Wenbin Huang, Doudou Li, Pingping Xiang, Yu Chen, Guofang Chen and Chao Liu Tags: Study Protocol Source Type: research
Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus
ConclusionCana effectively improved the dysregulated glucose metabolism in patients with T2DM. This improvement can potentially be attributed to the restoration of balance among the gut, oral, and ocular surface microbial communities.Clinical trial registrationhttps://www.chictr.org.cn/showproj.html?proj=56487, identifier ChiCTR2000034878. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - October 5, 2023 Category: Endocrinology Source Type: research
Role of canagliflozin in ameliorating isoprenaline induced cardiomyocyte oxidative stress via the heme oxygenase-1 mediated pathway
Biotech Histochem. 2023 Oct 2:1-13. doi: 10.1080/10520295.2023.2262390. Online ahead of print.ABSTRACTCanagliflozin (CZ) is commonly prescribed for management of type-2 diabetes mellitus (T2DM); it also can reduce the risk of myocardial infarction. We used 80 albino Wistar rats to investigate the cardioprotective potential of CZ against oxidative stress caused by administration of isoprenaline (ISO). We found that ISO stimulates production of reactive oxygen species and that CZ administration caused up-regulation of antioxidants and down-regulation of oxidants due to nuclear factor erythroid-2 related factor-2, as well as ...
Source: Biotechnic and Histochemistry - October 2, 2023 Category: Research Authors: Ahmed Ahmed Dina Abdel-Rahman Ehab M Hantash Source Type: research
Role of canagliflozin in ameliorating isoprenaline induced cardiomyocyte oxidative stress via the heme oxygenase-1 mediated pathway
Biotech Histochem. 2023 Oct 2:1-13. doi: 10.1080/10520295.2023.2262390. Online ahead of print.ABSTRACTCanagliflozin (CZ) is commonly prescribed for management of type-2 diabetes mellitus (T2DM); it also can reduce the risk of myocardial infarction. We used 80 albino Wistar rats to investigate the cardioprotective potential of CZ against oxidative stress caused by administration of isoprenaline (ISO). We found that ISO stimulates production of reactive oxygen species and that CZ administration caused up-regulation of antioxidants and down-regulation of oxidants due to nuclear factor erythroid-2 related factor-2, as well as ...
Source: Biotechnic and Histochemistry - October 2, 2023 Category: Research Authors: Ahmed Ahmed Dina Abdel-Rahman Ehab M Hantash Source Type: research
Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on 1,25-dihydroxyvitamin D and PTH
CONCLUSIONS: VitD deficiency rendered individuals more vulnerable to adverse effects of canagliflozin on biomarkers associated with bone health. VitD3 supplementation was protective against canagliflozin's short-term adverse effects on 1,25(OH)2D and PTH.PMID:37738423 | DOI:10.1210/clinem/dgad554 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 22, 2023 Category: Endocrinology Authors: Zhinous Shahidzadeh Yazdi Elizabeth A Streeten Hilary B Whitlatch May E Montasser Amber L Beitelshees Simeon I Taylor Source Type: research
Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on 1,25-dihydroxyvitamin D and PTH
CONCLUSIONS: VitD deficiency rendered individuals more vulnerable to adverse effects of canagliflozin on biomarkers associated with bone health. VitD3 supplementation was protective against canagliflozin's short-term adverse effects on 1,25(OH)2D and PTH.PMID:37738423 | DOI:10.1210/clinem/dgad554 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 22, 2023 Category: Endocrinology Authors: Zhinous Shahidzadeh Yazdi Elizabeth A Streeten Hilary B Whitlatch May E Montasser Amber L Beitelshees Simeon I Taylor Source Type: research
Comparative efficacy and safety of sodium-glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
In this study, the summarized WMDs and RRs were calculated using a pairwise analysis and a network meta-analysis with a random effects model, to compare and rank the efficacy and safety of SGLT-2i for renal outcomes in patients with T2DM. Among 1894 identified articles, 30 trials including 50,244 patients with T2DM were evaluated. Network analysis revealed that the administration of canagliflozin was associated with a reduced risk of renal impairment (surface under the cumulative ranking: 90.8%). Further, although the administration of SGLT-2i was not associated with the risk of renal impairment (RR = 0.88, 95%CI = 0.68-1....
Source: Renal Failure - September 19, 2023 Category: Urology & Nephrology Authors: Junhua Ma Jiancan Lu Peiling Shen Xuemei Zhao Hongling Zhu Source Type: research
Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation
In conclusion, our study showed that CANA re-sensitized HCC to CPT by inducing ferroptosis through dual effects on glycolysis and glutamine metabolism. This is a novel mechanism to increase chemosensitivity, which may provide compatible chemotherapy drugs for HCC.PMID:37696420 | DOI:10.1016/j.freeradbiomed.2023.09.006 (Source: Free Radical Biology and Medicine)
Source: Free Radical Biology and Medicine - September 11, 2023 Category: Biology Authors: Yuan Zeng Haoran Jiang Xiangting Zhang Jun Xu Xiao Wu Qian Xu Weimin Cai Huiya Ying Ruoru Zhou Yingrong Ding Kanglei Ying Xian Song Zhuoyan Chen Liuwei Zeng Luying Zhao Fujun Yu Source Type: research
